Patients with HR+/HER2- early-stage breast cancer had a strong preference for a lower risk of AEs, and therefore preferred treatment regimens that were more similar to those that were received with the clinical experience of similar ribociclib treatment regimens. The gene discussed is HR; the disease is breast carcinoma.